XML 73 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration and License Agreements - Schedule of Significant Changes in Deferred Revenue Balances, Antibody Collaboration (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Disaggregation of Revenue [Line Items]      
(Decrease) increase in deferred revenue $ (194.5) $ (113.1) $ 244.3
Sanofi Collaboration Agreement, Antibody      
Disaggregation of Revenue [Line Items]      
(Decrease) increase in deferred revenue 251.6    
Revenue recognized that was included in deferred revenue at the beginning of the period $ (133.2)